How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?

For instance, how would you manage a patient with both EGFR L858R and EGFR A647T mutations? Additionally, does the presence of brain metastasis influence your treatment strategy?

Answer from: Medical Oncologist at Academic Institution

This is certainly a quite challenging question- both based on the content of the question, then on the key additional context that is left out of the question as to the myriad other pieces of information that the oncologist post ELCC 2025 and the now available OS results from MARIPOSA will need to g...

Please select the option that best describes you:

How would you approach the management of a patient with Stage IV NSCLC harboring both a classical and non-classical compound EGFR mutations?

Related Questions